PubRank

Glenda Halliday

Author PubWeight™ 55.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007 8.10
2 Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2009 4.73
3 Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 2008 4.73
4 Missing pieces in the Parkinson's disease puzzle. Nat Med 2010 2.90
5 Dementia with Lewy bodies. Lancet Neurol 2004 2.66
6 A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 2013 2.32
7 Multiple biological pathways link cognitive lifestyle to protection from dementia. Biol Psychiatry 2011 1.79
8 Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain 2005 1.41
9 PART is part of Alzheimer disease. Acta Neuropathol 2015 1.31
10 Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004 1.30
11 An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathol 2006 1.24
12 The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol 2007 1.21
13 In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease. Brain 2012 1.11
14 A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Struct Funct 2011 1.09
15 TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol 2014 1.08
16 Genetic contributions to Parkinson's disease. Brain Res Brain Res Rev 2004 1.04
17 c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum Mol Genet 2014 1.03
18 Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol 2010 0.96
19 Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics 2006 0.95
20 Relationship between hippocampal volume and CA1 neuron loss in brains of humans with and without Alzheimer's disease. Neurosci Lett 2004 0.93
21 Pyramidal cell loss in motor cortices in Huntington's disease. Neurobiol Dis 2002 0.92
22 Can we clinically diagnose dementia with Lewy bodies yet? Transl Neurodegener 2013 0.92
23 Localization of copper and copper transporters in the human brain. Metallomics 2013 0.90
24 The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol 2007 0.86
25 VISA--a pass to innate immunity. Int J Biochem Cell Biol 2006 0.85
26 Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer's disease. Curr Alzheimer Res 2011 0.83
27 Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. Biochim Biophys Acta 2010 0.83
28 DNA extraction from fresh-frozen and formalin-fixed, paraffin-embedded human brain tissue. Neurosci Bull 2013 0.81
29 Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease. Mov Disord 2012 0.80
30 Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. J Neurochem 2005 0.80
31 Tenuigenin attenuates α-synuclein-induced cytotoxicity by down-regulating polo-like kinase 3. CNS Neurosci Ther 2013 0.79
32 Clarifying the pathological progression of Parkinson's disease. Acta Neuropathol 2008 0.77
33 A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. Neurosci Lett 2007 0.77
34 Role of hippocalcin in mediating Aβ toxicity. Biochim Biophys Acta 2012 0.77
35 An evidence base for noradrenergic deficits in Parkinson's disease. Mov Disord 2012 0.75
36 Progressive supranuclear palsy finally has a clinically measureable τ abnormality. J Neurol Neurosurg Psychiatry 2014 0.75
37 Clarifying Lewy-body parkinsonism with visual hallucinations. Lancet Neurol 2005 0.75
38 Misfolded proteins in Huntington disease fetal grafts: further evidence of cell-to-cell transfer? Ann Neurol 2014 0.75
39 Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease. Neurodegener Dis 2013 0.75
40 Partial lesion of thalamic ventral intermediate nucleus after chronic high-frequency stimulation. Mov Disord 2004 0.75